Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Basliea

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

- PMLiVE

Astellas appoints ethics and compliance and US legal leaders

Mark Wanda, Nahrin Marino and Matt Silversten take up new roles

- PMLiVE

Astellas names Bob Chib to development leadership role

He takes up corporate strategy and planning position

- PMLiVE

Astellas’ EMEA president Ken Jones resigns

He will be succeeded by the firm's marketing head Yukio Matsui

- PMLiVE

Should We Care About Rare Diseases? By Alastair Kent

Alastair Kent, OBE, the Director of Genetic Alliance UK and chair of Rare Disease UK tells us why it’s so important to care about rare disease and why we should...

Say Communications

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Research Partnership

- PMLiVE

Astellas appoints new president of its Americas operations

James Robinson replaces Masao Yoshida

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

- PMLiVE

First von Willebrand disease therapy heads new FDA approvals

Baxalta's Vonvendi set for an early 2016 launch in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links